Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells

  1. Barna D. Fodor1,
  2. Stefan Kubicek1,
  3. Masato Yonezawa,
  4. Roderick J. O’Sullivan,
  5. Roopsha Sengupta,
  6. Laura Perez-Burgos,
  7. Susanne Opravil,
  8. Karl Mechtler,
  9. Gunnar Schotta, and
  10. Thomas Jenuwein2
  1. Research Institute of Molecular Pathology (IMP), The Vienna Biocenter, A-1030 Vienna, Austria
  1. 1

    1 These authors contributed equally to this work.

Abstract

Histone lysine trimethyl states represent some of the most robust epigenetic modifications in eukaryotic chromatin. Using a candidate approach, we identified the subgroup of murine Jmjd2 proteins to antagonize H3K9me3 at pericentric heterochromatin. H3K27me3 and H4K20me3 marks are not impaired in inducible Jmjd2b-GFP cell lines, but Jmjd2b also reduces H3K36 methylation. Since recombinant Jmjd2b appears as a very poor enzyme, we applied metabolic labeling with heavy methyl groups to demonstrate Jmjd2b-mediated removal of chromosomal H3K9me3 as an active process that occurs well before replication of chromatin. These data reveal that certain members of the jmjC class of hydroxylases can work in a pathway that actively antagonizes a histone lysine trimethyl state.

Keywords

Footnotes

  • 2

    2 Corresponding author.

    2 E-MAIL jenuwein{at}imp.univie.ac.at; FAX 43-1-798-7153.

  • Supplemental material is available at http://www.genesdev.org.

  • Article published online ahead of print. Article and publication date are online at http://www.genesdev.org/cgi/doi/10.1101/gad.388206

    • Received November 30, 2005.
    • Accepted April 26, 2006.
| Table of Contents

Life Science Alliance